Alzheimer's disease (AD) is a progressive neurodegenerative disease which cannot be prevented, cured, or decelerated. About 10--20% of people older than 45 in the US are at risk of developing AD in their life ([@bib9]). Genetic and epidemiological studies have associated variation in several genes strongly to AD. Gain-of-function mutations in amyloid precursor protein (*APP*) or in presenilin genes related with processing APP are associated to early-onset AD ([@bib21]). Possession of extra wild-type copies of *APP*, such as found in Down Syndrome (DS) or in rare individuals without DS, is also associated to early-onset AD ([@bib65]; [@bib6]). Additionally, a distinct variant of *APP* appears protective against AD ([@bib33]). The strongest genetic risk factor for the more common late-onset AD is the ε4 allele of apolipoprotein E (*APOE4*) ([@bib12]; [@bib39]). Over 65--80% of AD patients carry an *APOE4* allele ([@bib49]; [@bib17]). The lifetime risk for AD in people homozygous for *APOE4* is extremely high (91%) relative to those with the more common *APOE3* allele (20%) or the less common *APOE2* allele (2.8--4.5%) ([@bib12]; [@bib13]). *APOE4* is associated with more pronounced neurodegeneration ([@bib27]); consequently, each copy of *APOE4* predicts shorter lifespan relative to the more common *APOE3* variant ([@bib39]). Even for early-onset AD, the *APOE4* variant is associated with earlier onset and harsher severity, including elevating levels of the amyloid-β~1-40~ peptide and faster spread of neurodegeneration in the case of Down syndrome ([@bib48]; [@bib26]). This suggests that *APP* and *APOE4* may contribute an additive or synergistic risk for AD onset and progression.

Despite the substantial influence of *APOE4* on the progression of AD, how APOE4 modulates the molecular mechanisms underlying neurodegeneration remains elusive. Study of genetically modified mice has contributed to our understanding of the susceptibility to AD and other neurodegenerative diseases conferred by mutations or variants in *APP*, *APOE*, and related genes ([@bib15]). However, progress toward understanding the mechanistic underpinnings of some AD-related pathologies, particularly neurodegeneration, has been slower ([@bib36]). Many mouse models of AD do not show neurodegeneration that is central to the human condition ([@bib32]). Moreover, it is more expensive and time-consuming to study age-related diseases in mice.

To surmount some of these limitations, we explored whether *APOE* could be studied in the context of *APP*-related neurodegeneration with the genetically tractable model nematode, *Caenorhabditis elegans* ([@bib61]). This minimal *in vivo* animal model offers several advantages for basic and applied research for AD. First, worms mature rapidly to adulthood, reaching "middle-age" of adulthood in only 5 days as reproduction declines. Despite this compressed lifespan, *C. elegans* shares many of the genetic, cellular, and molecular processes of aging with humans and mice ([@bib3]). Thus, age-dependent processes can be studied within the span of one week with *C. elegans*. Second, forward and reverse genetics as well as transgenesis studies are extremely rapid with *C. elegans*. Third, every cell in the tiny (1 mm) worm is identified, including its 302 neurons, which can be examined individually using fluorescent reporters in the living, transparent worm. The function and health of even single identified neurons can be further probed by quantifying simple behaviors such as egg laying and locomotion. Fourth, several models of neurodegeneration related to AD have been generated using *C. elegans* ([@bib23]). We recently described a transgenic worm strain that expresses a single copy of human *APP* and displays degeneration of a subset of cholinergic neurons in middle-age adulthood ([@bib61]; [@bib44]). Using this *APP*-expressing strain, we discovered small molecules that both prevent degeneration of neurons in worm via a conserved signaling pathway and boost cognition in a mouse model of AD ([@bib61]). Thus, although the simple worm cannot be used to study the important decline in cognition and memory as in mouse models, it can be used to directly study degeneration of identified neurons and to indirectly predict effective pharmacological approaches in rodent models of AD.

In this study, we tested how expressing variants of human *APOE* altered health and function of neurons in our worm model of *APP*-related neurodegeneration. We observed several key characteristics associated with AD. First, *APOE4* caused a higher level of neurodegeneration than *APOE3* and, *APOE4* but not *APOE3* acted in concert with *APP* to further increase neurodegeneration. This retains the variant-specific effect of *APOE* that is well-documented in humans ([@bib12]). Second, *APOE4* accelerated neurodegeneration in *C. elegans*, lowering the age of onset from late to early adulthood. This mirrors the expedited onset of degeneration in humans who carry *APOE4* ([@bib27]). Lastly, despite deliberate expression of *APP* and *APOE4* throughout the nervous system, the pattern of neurodegeneration in the worm model was restricted. This result is similar to the initially restricted degeneration of specific brain regions, *i.e.*, the hippocampus and the entorhinal cortex, despite the near-ubiquitous expression of APP and APOE in the brain seen in AD patients ([@bib27]). Because *APOE* variant expression influences *C. elegans* neurodegeneration in a manner similar to several key aspects found in human AD, our worm model may facilitate both the discovery of molecular pathways involved in the development of AD as well as novel drugs for the treatment of AD.

Materials and Methods {#s1}
=====================

Plasmid and transgenic animals {#s2}
------------------------------

The plasmid constructs for human *APP* or *APOE* transgenes under a pan-neuronal promoter (*prab-3*::*APP*::*mCherry*::*UNC-54* UTR; *prab-3*::*APOE4*::*UNC54* UTR; *prab-3*::*APOE3*::*UNC54* UTR) were generated using Multi-site Gateway technology (Invitrogen, Carlsbad, CA). Middle entry clones were made using the MultiSite Gateway Three-Fragment Vector Construction Kit (Invitrogen). cDNA for human *APP695* or *APOE* variants (*APOE3* or *APOE4*) was amplified using the High Fidelity Phusion Polymerase (NEB) and recombined into pDONR221 using the BP clonase (Invitrogen). To generate the expression clones, the middle entry clones were previously fused into pCFJ150 along with the 5′ [*rab-3*](https://identifiers.org/bioentitylink/WB:WBGene00004267?doi=10.1534/g3.120.401486) pan-neuronal promoter and 3′ [*unc-54*](https://identifiers.org/bioentitylink/WB:WBGene00006789?doi=10.1534/g3.120.401486) UTR entry clones ([@bib61]) using the LR clonase II (Invitrogen). Resulting plasmids were verified by sequencing. The construct for the GFP reporter for HSN neurons was made by a PCR fusion of a ∼2 kb region upstream of [tph-1](https://identifiers.org/bioentitylink/WB:WBGene00006600?doi=10.1534/g3.120.401486) amplified from genomic DNA and *GFP*::*unc-54* UTR amplified from pPD95.75. The construct for the GFP reporter for VA and VB neurons was made by a PCR fusion of a ∼1.8 kb region upstream of [*del-1*](https://identifiers.org/bioentitylink/WB:WBGene00000952?doi=10.1534/g3.120.401486) amplified from genomic DNA and *GFP*::*unc-54 UTR* amplified from pPD95.75. The constructs to express *APOE4* in the intestine and coelomocytes were made via NEBuilder HiFi DNA Assembly. The promoter of [*fat-7*](https://identifiers.org/bioentitylink/WB:WBGene00001399?doi=10.1534/g3.120.401486) (∼1.2 kb upstream of the gene) was amplified from genomic DNA while the promoter of [*unc-122*](https://identifiers.org/bioentitylink/WB:WBGene00006845?doi=10.1534/g3.120.401486) (∼300 bp) was amplified from pCFJ68.

Single copy transgenic strains for human *APP* and *C. elegans*[*apl-1*](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486) were generated via MosSCI methods as described by Frøkjaer-Jensen *et al.* (2008). A single copy of human *APP* or [*apl*-1](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486) under a [*rab-3*](https://identifiers.org/bioentitylink/WB:WBGene00004267?doi=10.1534/g3.120.401486) promoter was inserted into the chromosome II. The EG4322 strain was selected for the insertion of the construct at [ttTi5605](https://identifiers.org/bioentitylink/WB:WBVar00254893?doi=10.1534/g3.120.401486) II. Insertion of *APP* or [*apl-1*](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486) was confirmed by PCR and sequencing of the modified region on the chromosome. Extrachromosomal array strains in this study were made by injecting expression plasmids and co-injection markers (1.2 ng/μl for pCFJ90, *pmyo-2:mCherry*, and 30 ng/μl for pCFJ68, *punc-122*::*GFP*, *ptph-1*::*GFP*) described by ([@bib43]). The extrachromosomal array for *ptph-1*::*GFP* was subsequently integrated using standard UV-integration techniques and outcrossed 6 times; this JPS617 strain served as the wild-type (WT) background for all other strains.

We made three attempts to integrate the extrachromosomal array expressing *APOE4* using traditional UV-integration techniques. However, the attempts were unsuccessful, at least in part due to a low survival rate after UV exposure. Instead, the array \[*prab-3*::*APOE4*::*UNC54 UTR*; *pmyo-2:mCherry*\] was integrated using CRISPR-cas9-based methods modified from [@bib62]. Briefly, two plasmids containing the *cas9* gene (pDD162) and a guide RNA targeting either the genomic region of integration (LG X:22.84, a location previously used for MosSCI insertions ([@bib18])) or a region on the extrachromosomal array (β-lactamase gene), and a co-injection marker (pCFJ104, *pmyo-3:mCherry*) were injected into worms carrying the *APOE4* array. The sequences for guide RNAs used in the integration are as follow, 5′TTAATAGACTGGATGGAGG3′ (β-lactamase gene), 5′ATGTGTCATAAGTCAACAAC3′ and 5′TTATGTAGTCTCTTTCAGTG3′ (X:22.84). The guide RNAs were made according to [@bib56]. After integration of the linearized array, we chose a strain with a similar intensity of red pharynx as that seen prior to integration. The same method was employed by SunyBiotech (Fuzhou City, China) to generate an integrated APOE3 strain PHX2443 *sybIs2443\[prab-3*::*ApoE3*::*unc-54 UTR*, *pmyo-2*::*mCherry*::*unc-54 UTR\]*.

The integrated *APOE4* and *APOE3* lines were crossed to JPS617 to make the APOE4 (JPS844) and APOE3 (JPS1312) strains with GFP-labeled VC and HSN neurons. JPS844 was then crossed to JPS809 to make APOE4+APP (JPS845) strains with GFP-labeled VC and HSN neurons. Subsequently, JPS845 was crossed with MT3002 ([*ced-3*](https://identifiers.org/bioentitylink/WB:WBGene00000417?doi=10.1534/g3.120.401486)*(*[*n1286*](https://identifiers.org/bioentitylink/WB:WBVar00090093?doi=10.1534/g3.120.401486)*)* IV) to obtain an APOE4+APP strain with a [*ced-3*](https://identifiers.org/bioentitylink/WB:WBGene00000417?doi=10.1534/g3.120.401486) null background. The genotypes for all the strains used in this study are listed in Table S1.

Bag of worms assay {#s3}
------------------

Worms were maintained at 20° as previously described by Brenner (1974). A total of 50 worms were age-synchronized by picking L4-stage larvae onto NGM agar plates seeded with OP50 bacteria. Adult worms were carefully examined every day for up to four days (Day 1-4 of adulthood) for the bag-of-worms (BW) phenotype indicated by the presence of hatched larvae within their body. Groups of healthy worms with no hatched larvae were transferred to a freshly seeded plate each day. The reported percentage BW represents the number of BW observed over the period of observation (2-4 days) relative to the total number of assayed worms. The assay was repeated 3-4 times for each genotype at different times to control for conditions that may vary by date. BW phenotype was quantified as a percentage ± 95% confidence interval. Group comparisons were made with planned *χ^2^*-tests.

Scoring of neurodegeneration {#s4}
----------------------------

Worms were maintained at 20° and synchronized by picking L4-stage larvae onto NGM plates seeded with OP50 bacteria and containing 0.35-mM 5-fluoro-2'-deoxyuridine-5′-phosphate (FUDR) to sterilize adults and prevent non-specific consequences of larvae hatching inside adults. Prior to scoring neuron health, worms were cleaned by transferring them to an unseeded plate until they left no residual tracks of bacteria, a process that took ∼10 min. Worms were mounted on 2% agarose pads, immobilized with 30-mM sodium azide and imaged on an Olympus IX51 inverted microscope equipped with an X-Cite FIRE LED Illuminator (Excelitas Technologies Corp.) and an Olympus UPlanFL N 40X/0.75 NA objective. Epifluorescence images were taken with a Retiga 2000R CCD camera (QImaging) and QCapture Pro 6.0 software. For [Figures 2C](#fig2){ref-type="fig"} and [3C](#fig3){ref-type="fig"} worms were identically maintained, but immobilized mechanically without azide on a microfluidic vivoChip (Newormics, Austin, TX) in filtered M9 buffer and imaged at 40X. For strains with no or extrachromosomal expression of *APOE* ([Figure 1](#fig1){ref-type="fig"}), HSN neurons were considered healthy when the scored HSN cell body was clearly present and the processes were intact. HSNs were considered degenerated when the scored neuron was absent and/or displayed significant morphological abnormalities (*e.g.*, blebbing, beading and absence of processes). Examples of degenerated HSN neurons following these criteria can be found in Fig. S1. We observed dimmer GFP expression in the HSNs of integrated *APOE4* strains ([Figure 3](#fig3){ref-type="fig"}) making it more difficult to visualize the HSN processes. Thus, HSN health in these strains (JPS844 and JPS845) was based exclusively on the presence or absence of the HSN cell-bodies. That is, HSNs were considered to be degenerated when the scored HSN neurons were absent. Neuron health was scored with the observer blind to genotype. An average of 50 worms were scored per strain for each trial. Scoring was repeated 3-4 times for each genotype and expressed as percent HSN degeneration ± 95% confidence interval. Group comparisons were made with planned *χ^2^*-tests.

![Pan-neuronal expression of *APOE4* induces neurodegeneration in HSN neurons that is exacerbated by *APP*. *A*, Histogram shows the cumulative percent bag-of-worms (BW) phenotype during the first 3 days of adulthood. BW was determined by the presence of progeny with pharyngeal mCherry expression in a hermaphrodite. Two strains of each genotype (signified by grouped pairs of solid and open bars) were made with independent extrachromosomal arrays containing a *pmyo-2*::*mCherry* reporter. The *APP* transgene was integrated in all *APP* strains. The BW phenotype was frequently observed in *APOE4* strains with or without *APP* but not in strains with *APP* alone. In contrast, *APOE3* transformed at the same concentration as *APOE4* (exAPOE3) or double the concentration (exAPOE3h), did not increase the frequency of BW. For statistical comparisons, solid and open bars were each treated as a set. Within a set, all pairwise comparisons were made with χ^2^ tests. Alpha was set at 0.001 to correct for multiple comparisons (\**P* \< 0.001). *B*, Fluorescent images of the neurons, HSNL and HSNR, in Day 3 adults. Many *APOE4* worms with or without *APP* showed morphological abnormalities or a total loss of one or both HSN neurons. Arrowheads indicate healthy HSN neurons. Dotted circles indicate degenerated neurons. *C*, Histogram shows the percent HSN neurodegeneration on Day 3 of adulthood for a set of strains assayed in *A*. Pairwise comparisons were made with χ^2^ tests. Alpha was set at 0.003 to correct for multiple comparisons (\**P* \< 0.003).](2851f1){#fig1}

Locomotion assay {#s5}
----------------

Worms were cleaned of bacteria as described above. Approximately 15 worms were moved into a 5/8-inch-diameter copper ring sealed on a standard unseeded NGM agar plate. Movement was recorded for 2 min at 2 frames/sec with a FLEA digital camera (Point Gray, Richmond, BC, Canada). The distance that the worms crawled during 1 min was measured using a semi-automated procedure in ImagePro Plus (Media Cybernetics, Rockville, MD) to objectively calculate overall speed of individual worms. Speed for each group was quantified as group mean ± SEM. Group comparisons were made with planned Student's *t*-tests.

Semi-quantitative PCR {#s6}
---------------------

Five worms of each genotype (WT, integrated *APOE3*, integrated *APOE4*, extrachromosomal *APOE3*, extrachromosomal *APOE4*) were lysed and digested in buffer + proteinase K for one hour. PCR was performed using 2 μl of template for each reaction with 2x DreamTaq Green Master Mix (FisherSci) and primers: forward 5′-CGGACATGGAGGACGTG-3′, reverse 5′-AGCCGCTTACGCAGCTTG-3′. Samples were run on a 1.5% agarose gel at 150V for 40min and imaged on a BioRad UV Imager. Images were exported into Image Lab (BioRad), where lanes and bands were manually selected, and band intensity was measured. Adjusted band intensities were exported into Prism 8 (GraphPad), and data are presented as mean ± SEM. Three independent biological replicates were measured for each genomic preparation.

RT-qPCR {#s7}
-------

Worms were washed from near-starved plates (3 plates for WT and integrated, 9 plates for extrachromosomal) and pelleted. Each pellet was flash frozen in liquid nitrogen, thawed on ice, and vortexed 6 times. The pellet was further disrupted by needle and syringe in RNA extraction buffer. RNA was isolated (Zymo *Quick*-RNA Miniprep; QIAGEN RNeasy Mini Kit), and 1ug was reverse transcribed into cDNA with the Protoscript II cDNA synthesis kit (NEB). qPCR was performed using SYBR Green (FisherSci) on a Roche 480 Lightcycler (Roche) using primers: *APOE* forward 5′-CCTGGACGAGGTGAAGGAGCA-3′, reverse 5′-CTCGAACCAGCTCTTGAGGC-3′ and [*tba-1*](https://identifiers.org/bioentitylink/WB:WBGene00006528?doi=10.1534/g3.120.401486) forward 5′-ATCTCTGCTGACAAGGCTTAC-3′, reverse 5′-GTACAAGAGGCAAACAGCCAT-3′. Ct values were exported and analyzed using the ΔCt method. No values were detected for no template and no RT controls. Data represents the mean of two biological replicates with three technical replicates each. The housekeeping gene [*tba-1*](https://identifiers.org/bioentitylink/WB:WBGene00006528?doi=10.1534/g3.120.401486) was used as a control, and relative expression was normalized to this reference gene.

Data availability {#s8}
-----------------

Strains and plasmids are available upon request. The authors affirm that all data necessary for confirming the conclusions of the article are present within the article, figures, and tables. Table S1 contains genotypes for each strain used in this study. Supplemental material available at figshare: <https://doi.org/10.25387/g3.12493769>.

Results {#s9}
=======

APP expression exacerbates APOE4-induced neurodegeneration in HSN neurons {#s10}
-------------------------------------------------------------------------

We previously developed a *C. elegans* model of neurodegeneration that expressed a single-copy of human *APP* and showed age-related degeneration of a subset of cholinergic neurons ([@bib61]; [@bib44]). Specifically, six VC-class neurons located in the middle of the ventral nerve cord begin to die as the worm advances past Day 3 of adulthood. To investigate whether variants in *APOE* modify neurodegeneration phenotypes in our APP worm model, we generated strains that expressed human *APOE4* or *APOE3*, with or without human *APP*. Both *APP* and *APOE* transgenes were expressed throughout the nervous system using the conventional pan-neuronal [*rab-3*](https://identifiers.org/bioentitylink/WB:WBGene00004267?doi=10.1534/g3.120.401486) promoter to mimic widespread brain expression in mammals ([@bib52]). *APP* was tagged with mCherry at the C-terminus and was found to be expressed throughout the nervous system of the worm (Fig. S2). *APOE* expression was verified via RT-qPCR (Fig. S3). *APP* was integrated while initially *APOE* transgenes were expressed with extrachromosomal arrays. Comparisons were made between these strains and a wild-type background (WT). While studies have shown a neuroprotective effect of APOE2 in humans and other models ([@bib10]; [@bib57]; [@bib24]; [@bib47]), our study focused only on the effects of human *APOE3* or *APOE4* expression.

Despite the degeneration of VC neurons in our *APP*-expressing strain, the expression of human *APP* alone did not confer any obvious behavioral defects ([@bib44]). To test if *APOE* variants caused gross phenotypic differences that may be indicative of neuronal degeneration or dysfunction beyond that observed in our strain only expressing *APP*, we evaluated the behavior of *APOE3*- or *APOE4*-expressing strains. We observed an increase in a behavioral phenotype called 'bag-of-worms' (BW) in strains expressing *APOE4* but not *APOE3* ([Figure 1A](#fig1){ref-type="fig"}). *C. elegans* normally lays eggs that hatch outside the parent. However, eggs are retained inside the parent under stressful conditions of starvation, or when the neurons that mediate egg-laying become dysfunctional or die ([@bib51]). If eggs are retained too long in the worm, they hatch and fill the parent with writhing larvae (Angelo and Van Glist 2009). This BW phenotype can be unambiguously detected at low power via a stereomicroscope and has proven convenient to study many biological processes (*e.g.*, [@bib54]; [@bib11]).

When we quantified the amount of BW by observing worms for 3 days throughout the *C. elegans* reproductive period, we found that WT worms displayed a low level of BW as expected. The incidence of BW was not raised in strains expressing *APP* or *APOE3*. However, *APOE4*-expressing strains had a significantly higher percentage of BW than WT, *APP*-, and *APOE3*-expressing strains ([Figure 1A](#fig1){ref-type="fig"}). Worms expressing both *APOE4* and *APP* (APOE4+APP) displayed an even higher incidence of BW than worms expressing either *APOE4* or *APP* alone ([Figure 1A](#fig1){ref-type="fig"}). In contrast, the percentage BW in strains expressing APOE3+APP remained low and was not significantly higher than that found in strains expressing either gene individually ([Figure 1A](#fig1){ref-type="fig"}). The lack of effect of *APOE3* could not be easily explained by a lower number of *APOE3* transgene copies on the extrachromosome *vs.* *APOE4* copies because an independent strain made with a higher (2x) transformative dose (exAPOE3h) showed a low level of BW indistinguishable from the APP strain ([Figure 1A](#fig1){ref-type="fig"}).

Because the *APOE4*-expressing strains displayed the BW phenotype even when well-fed, this suggested that one or more of the egg-laying neurons were dysfunctional or dying. Egg-laying is controlled primarily by the left-right pair of HSN neurons and to a much lesser extent by VC4 and VC5 neurons ([@bib51]). The HSN and VC4 and VC5 cholinergic neurons connect reciprocally, as well as to egg-laying muscles by synapses ([@bib1]). We checked the health of these neurons by directly visualizing them with a fluorescent reporter through the worm's transparent body (see Methods). We considered HSN neurons "degenerated" when the neuron was absent and/or displayed significant morphological abnormalities (*e.g.*, blebbing, beading and absence of processes) (see [Figures 1B](#fig1){ref-type="fig"} and S1). Additionally, we saw clear degeneration of HSN neurons in *APOE4*-expressing strains with or without co-expression of *APP*. Consistent with our observed BW behavior, the incidence of HSN neuron degeneration was significantly higher in APOE4+APP worms than those expressing either *APP* or *APOE4* alone ([Figure 1C](#fig1){ref-type="fig"}). Intriguingly, although expression of *APOE4* increased degeneration of HSN neurons, the expression of *APOE3* with or without *APP* co-expression did not increase HSN degeneration relative to WT ([Figure 1C](#fig1){ref-type="fig"}). Even when the *APOE3* transgene was transformed at double the concentration of the *APOE4* transgene and combined with *APP* expression, the resulting strains exhibited a percentage BW and HSN neurodegeneration that was not significantly higher than WT ([Figure 1A,C](#fig1){ref-type="fig"}).

Reminiscent to our previous findings with APP alone, APOE4-induced neurodegeneration increased in an age-dependent manner, from few at Day 1 of adulthood to many by Day 3 of adulthood ([@bib61]; [@bib44]). As BW behavior results in death of the adult, our sample size was too diminished to study older (\> day 4) adults.

Others have found that APOE4 may worsen outcomes in AD patients and models via several mechanisms, including some that depend on APP. For instance, APOE4 exacerbates Aβ deposition in transgenic models, though a direct interaction between APOE4 and APP has not been shown ([@bib60]; [@bib4]; [@bib5]; [@bib34]; [@bib40]). Although *C. elegans* does not have a clear ortholog of *APP*, it has a related gene, [*apl-1*](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486), with 71% sequence similarity to the intracellular domain of APP ([Figure 2A](#fig2){ref-type="fig"}; [@bib14]). *C. elegans* lacks a clear β-secretase ortholog, suggesting an Aβ-like fragment would not be processed from either human APP or [APL-1](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486). Importantly, [APL-1](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486) has no Aβ domain. Nevertheless, we decided to test whether APOE4-induced degeneration of HSN neurons depended on [*apl-1*](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486). However, we could not easily test whether APOE4-induced neurodegeneration required [*apl-1*](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486) by knocking it out, because [*apl-1*](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486) is essential for development ([@bib28]). Instead, we tested whether knocking in an extra copy of [*apl-1*](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486) mimicked the synergistic effects of knocking in *APP*. Specifically, we integrated a single additional copy of [*apl-1*](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486) expressed pan-neuronally and tagged with mCherry (SC_APL-1). The SC_APL-1 strain also served as a control for knocking a single mCherry-tagged transgene into a specific locus on the second chromosome in our APP model.

![Overexpression of APP-related *C. elegans* gene [*apl-1*](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486) does not mimic APP in elevating APOE4-induced neurodegeneration. *A*, Species alignment to the 31 residues of the human [A]{.ul}PP [i]{.ul}ntra[c]{.ul}ellular [d]{.ul}omain (AICD). Shaded residues are identical to human sequence, and boxes indicate conservative changes. *B*, Single-copy (SC) overexpressed [*apl-1*](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486) is protective against bag-of-worms phenotype in an *APOE4* background. Histogram showing the cumulative percent bag-of-worms phenotype during the first 4 days of adulthood. Bag-of-worms was determined by visualization of larval worm within the body of a hermaphrodite under stereomicroscope. Solid and open bars represent trials compared to different SC [*apl-1*](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486) controls. For statistical comparisons, solid and open bars were compared to their respective controls. Comparisons were made with χ^2^ tests. *C*, APOE4-induced HSN neurodegeneration is diminished in SC [*apl-1*](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486) background. Histogram showing the percent HSN neurodegeneration for Day 1 and Day 3 adults. Comparisons were made with χ^2^ tests.](2851f2){#fig2}

We generated strains expressing both *SC_apl-1* and *APOE4* and tested for BW and HSN neurodegeneration. Overexpression of [*apl-1*](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486) alone did not result in an incidence of BW above WT levels. Interestingly, expression of *SC_apl-1* with *APOE4* showed an unexpected, significant reduction in BW compared to *APOE4* alone ([Figure 2B](#fig2){ref-type="fig"}) suggesting that HSN function was retained. Consistent with these behavioral results, we found that HSN neurodegeneration was reduced in APOE4+SC_APL-1 strains compared to APOE4+APP strains ([Figure 2C](#fig2){ref-type="fig"}). We conclude that the BW and neurodegeneration phenotypes seen in our *APOE4*-expressing strain is not exacerbated by over-expression of [*apl-1*](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486). This suggests that APOE4 likely does not interact with [APL-1](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486) in the same way it does with APP to give rise to these phenotypes.

Taken together, these results demonstrate that the pan-neuronal expression of *APOE4* causes degeneration of the HSN neurons which happen to synapse with VC neurons. Further, co-expression of *APOE4* with *APP* extends the level of HSN neurodegeneration beyond that observed when either gene is expressed singly.

Neuronal APOE4 causes selective neurodegeneration {#s11}
-------------------------------------------------

Thus far, we used extrachromosomal arrays to express the *APOE* transgenes. Although extrachromosomal arrays represent a convenient approach to express transgenes, these arrays are not perfectly carried through cell division which gives rise to mosaic individuals ([@bib37]). Moreover, the expression of extrachromosomal transgenes is sometimes suppressed ([@bib29]). To control for these potential caveats, we sought to integrate the *APOE3* and *APOE4* transgene arrays into the worm's X chromosome and re-evaluate BW phenotype and HSN degeneration. In this way, the worm would be expected to faithfully express the *APOE3* and *APOE4* transgenes throughout the nervous system.

We again assayed BW and HSN neurodegeneration, breaking down the incidence as a function of age. The integrated APOE4 and APOE4+APP strains retained a comparable percentage of BW as observed in the extrachromosomal array strains by Day 3 of adulthood, while the integrated APOE3 strain did not exhibit significant phenotypes ([Figure 1A](#fig1){ref-type="fig"} *vs.* [Figure 3A](#fig3){ref-type="fig"}). Interestingly, not only was the total incidence of BW higher in the APOE4+APP strain by Day 3 of adulthood, but the total incidence of BW was already substantially raised by Day 2 of adulthood relative to that seen in the APOE4 strain ([Figure 3A](#fig3){ref-type="fig"}). Though both of the APOE4 and APOE4+APP strains showed age-dependent degeneration of HSN neurons, the degree of degeneration was highest in the APOE4+APP strain ([Figure 3C](#fig3){ref-type="fig"}). These results are consistent with our findings for the extrachromosomal strains. Differences in how APOE4 but not APOE3 strains displayed degeneration could not be simply attributed to higher levels of expression of the APOE4 transgene compared to APOE3. Both semi-quantitative genomic PCR and RT-qPCR revealed subtle but no significant differences in expression of both integrated and extrachromosomal transgenes (Fig. S3).

![Pan-neuronal co-expression of *APOE4* and *APP* induces age-related neurodegeneration in HSN neurons, not seen with *APOE3*. *A*, Histogram shows the cumulative percent bag-of-worms (BW) phenotype by Day 2 and Day 3 of adulthood. The frequency of the BW increased at an earlier age for the APOE4+APP strain than for the other genotypes. *APP*, *APOE3*, and *APOE4* transgenes were integrated. *B*, Fluorescent images of the neurons, HSNL and HSNR, in Day 3 adults. Integrated strains were scored based on a total loss of one or both HSN neurons. Arrowheads indicate healthy HSN neurons. Dotted circles indicate degenerated neurons. Dimmer GFP expression in the integrated *APOE4* strains (JPS844 and JPS845) made it difficult to see the HSN processes; therefore neurodegeneration was scored as the absence of HSN cell bodies in these strains. *C*, Histogram shows the percent HSN neurodegeneration for Days 1 and 3 adults. For *A* and *C*, pairwise comparisons within day and within-strain across days were made with χ^2^ tests. Alpha was set at 0.003 to correct for multiple comparisons (\**P* \< 0.003).](2851f3){#fig3}

When we expressed *APOE4* and *APP* throughout the nervous system, we originally expected to observe gross defects across multiple behaviors. However, aside from the BW phenotype, no gross movement defects were apparent in the APOE4+APP strain. Moreover, APOE4+APP worms exhibited no difference in crawling speed compared to WT worms ([Figure 4A](#fig4){ref-type="fig"}. The crawling speed was indistinguishable on both Day 1 and Day 3 of adulthood between WT and APOE4+APP worms ([Figure 4A](#fig4){ref-type="fig"}). Consistent with this behavioral observation, when we looked at GFP-labeled VA and VB cholinergic motor neurons, which contribute to locomotion, we saw no qualitatively discernable differences in morphology and number of VA and VB neurons between WT and APOE4+APP worms ([Figure 4B](#fig4){ref-type="fig"}).

![Neurodegeneration induced by pan-neuronal co-expression of *APOE4* and *APP* spares VA and VB neurons. *A*, Locomotion, a behavior mediated in part by VA and VB neurons, is not disrupted in APOE4+APP worms compared to WT worms. Histogram showing mean crawl speed ± SEM for WT and APOE4+APP worms on Days 1 and 3 of adulthood. Strain comparisons were made using Student's *t*-tests. *B*, Fluorescent images of the VA and VB neurons show no morphological abnormalities in Day 3 APOE4+APP adults relative to Day 1 APOE4+APP or WT adults. Arrowheads indicate healthy VA and VB neurons. Both *APP* and *APOE4* transgenes were integrated.](2851f4){#fig4}

Next, we asked whether *APOE4* induces neurodegeneration when expressed outside the nervous system in a pan-neuronal *APP* background. Using extrachromosomal arrays, we expressed *APOE4* in organs involved in metabolic and excretory functions, the intestine and coelomocytes, using the [*fat-7*](https://identifiers.org/bioentitylink/WB:WBGene00001399?doi=10.1534/g3.120.401486) and [*unc-122*](https://identifiers.org/bioentitylink/WB:WBGene00006845?doi=10.1534/g3.120.401486) promoters, respectively. Unlike with pan-neuronally expressed *APOE4*, the incidence of BW was as low for strains expressing *APOE4* in either coelomocytes or intestine as in the background *APP* strains ([Figure 5A](#fig5){ref-type="fig"}). This low percentage of BW for strains with *APOE4* expressed in coelomocytes or intestine corresponded with low levels of HSN degeneration in these strains ([Figure 5B,C](#fig5){ref-type="fig"}).

![Pan-neuronal, but not non-neuronal, expression of *APOE4* promotes HSN neurodegeneration in a pan-neuronal *APP* background. *A*, Histogram shows the cumulative percent bag-of-worms (BW) phenotype by Day 3 of adulthood. The frequency of the BW increased in worms with pan-neuronal *APP* when *APOE4* was expressed in neurons, but not in coelomocytes or intestine. Two strains of each genotype were made (signified by groups of paired solid and open bars) with independent extrachromosomal arrays containing a *pmyo-2*::*mCherry* and *APOE4* transgene. The *APP* transgene was integrated. For statistical comparisons, shaded bars and open bars were each treated as a set. Within a set, each exAPOE4 strain was compared with the background APP strain using χ^2^ tests. Alpha was set at 0.008 to correct for multiple comparisons (\**P* \< 0.008). *B*, Fluorescent images of the neurons, HSNL and HSNR, in Day 3 adults. Many worms expressing pan-neuronal *APOE4* on the *APP* background show morphological abnormalities or a total loss of one or both HSN neurons. Label indicates the location of *APOE4* expression. Arrowheads indicate healthy HSN neurons. Dotted circles indicate degenerated neurons. *C*, Histogram showing the percent HSN neurodegeneration on Day 3 of adulthood for a set of strains assayed in *A*. Each exAPOE4 strain was compared with the background APP strain using χ^2^ tests. Alpha was set at 0.015 to correct for multiple comparisons (\**P* \< 0.015).](2851f5){#fig5}

To better understand the mechanism of degeneration, we investigated whether HSN neurons degenerate in a manner dependent on apoptosis. We crossed the [*ced-3*](https://identifiers.org/bioentitylink/WB:WBGene00000417?doi=10.1534/g3.120.401486)*(*[*n1286*](https://identifiers.org/bioentitylink/WB:WBVar00090093?doi=10.1534/g3.120.401486)*)* null mutation into the integrated APOE4+APP strain. [CED-3](https://identifiers.org/bioentitylink/WB:WBGene00000417?doi=10.1534/g3.120.401486) is an executioner caspase that is part of the core apoptotic machinery in worm ([@bib63]). We found that the incidence of both BW and HSN neurodegeneration did not decrease in APOE4+APP strains with or without a mutation in this key apoptotic caspase ([Figure 6A-C](#fig6){ref-type="fig"}). Thus, pan-neuronal co-expression of *APOE4* and *APP* appears to cause HSN neurons to degenerate via a mechanism other than apoptosis.

![Neurodegeneration induced by pan-neuronal co-expression of *APOE4* and *APP* is not mediated by [CED-3](https://identifiers.org/bioentitylink/WB:WBGene00000417?doi=10.1534/g3.120.401486). *A*, Histogram shows the cumulative percent bag-of-worms (BW) phenotype by day 3 of adulthood. The frequency of BW in the APOE4+APP strain is not altered in a [*ced-3*](https://identifiers.org/bioentitylink/WB:WBGene00000417?doi=10.1534/g3.120.401486) null background. Both *APP* and *APOE4* transgenes were integrated. *B*, Likewise, [*ced-3*](https://identifiers.org/bioentitylink/WB:WBGene00000417?doi=10.1534/g3.120.401486) expression does not alter neurodegeneration in the APOE4+APP strain. Fluorescent images of HSNL and HSNR. Arrowheads indicate healthy HSN neurons. Dotted circles indicate degenerated neurons. *C*, Histogram showing the percent HSN neurodegeneration for Day 3 adults. Comparisons were made with χ^2^ tests.](2851f6){#fig6}

Discussion {#s12}
==========

In this study, we present a novel Alzheimer's disease model in *C. elegans*. Although the worm cannot model all aspects of human AD, our model mirrors three important characteristics: APOE variant-specific modulation of degeneration, age-dependent degeneration, and cell-specific patterned degeneration. In humans, the allele ε4 of *APOE* (*APOE4*) increases the risk as well as the mean age of clinical onset of AD in a copy-dependent manner ([@bib12]). The more common *APOE* variant in humans, *APOE3*, does not confer this relative risk. Our results show that *APOE4*, but not *APOE3*, causes degeneration in a subset of neurons in *C. elegans*. *APP* co-expression enhances this *APOE4*-related degeneration of the HSN neurons in *C. elegans*. By contrast, the HSN neurons do not appear to degenerate when *APP* is expressed alone. Similar APOE variant-specific effects have been observed in mouse models. In APOE-target replacement (TR) mouse models engineered on an amyloid-β transgenic background, pathological phenotypes, including amyloid-β deposition, are observed at a higher level in APOE4-TR mice than APOE3-TR mice ([@bib4]; [@bib19]). Further, compared to APOE2 and APOE3, APOE4 does not ameliorate neurodegeneration caused by amyloid-β deposition in the glutamatergic tail neurons of another *C. elegans* AD model ([@bib24]). However, studies that show a direct mechanistic link between *APP* and *APOE4* for neurodegeneration are still lacking.

In our *APOE4*-expressing strains, GFP-labeled HSN neurons display neurodegeneration by becoming dim, shrinking, forming blebs, and disappearing in many animals. We also found that the long axonal processes of HSN neurons, which extend anteriorly to synapse onto neurons in the nerve ring, undergo beading. This is reminiscent of how neuronal processes degenerate after laser axotomy ([@bib59]). Indeed, a recently published *C. elegans* AD model describes similar neurodegeneration patterns in the five glutamatergic tail neurons in the presence of Aβ ([@bib24]). In mice, targeted replacement of ApoE with human APOE4 causes dendrites of neurons in the amygdala to shrink compared to the dendrites of APOE3-TR mice ([@bib35]). These shared morphological changes in the processes of dying neurons suggest that there might be conserved pathways for degeneration.

Notably, we found that expression of *APOE4* on its own was sufficient to induce significant HSN neurodegeneration and its associated bag-of-worms behavioral phenotype. In contrast, [@bib24] found that APOE4 expression did not appear to cause neurodegeneration in *C. elegans*. These different results may be explained by our pan-neuronal *vs.* their restricted glutamatergic expression of APOE4. Prevailing hypotheses suggest the interaction between APOE4 and the Aβ fragment drives AD progression. However, a number of studies in mice have shown that APOE4 alone can influence AD progression by affecting numerous, Aβ-independent processes including impaired learning behaviors, reduced synaptic plasticity and neurogenesis, increased neuroinflammation, neurotoxicity of fragmented APOE4, impaired mitochondrial function, and increased tauopathy (Yadong [@bib30]; [@bib58]). Many of these processes may be tested in worm. In fact, *C. elegans* contains an ortholog to human tau, [PTL-1](https://identifiers.org/bioentitylink/WB:WBGene00004212?doi=10.1534/g3.120.401486), that shows 50% sequence conservation in the microtubule-binding repeats ([@bib22]). Future studies may test how [*ptl-1*](https://identifiers.org/bioentitylink/WB:WBGene00004212?doi=10.1534/g3.120.401486) influences APOE4-induced neurodegeneration in our model. One of the prominent characteristics of AD is age-dependent neurodegeneration. Co-expression of *APP* with *APOE4* throughout the nervous system in *C. elegans* enhances the incidence of *APOE4*-related neurodegeneration. Interestingly, the cumulative effect of *APP* and *APOE4* expression manifests more strongly in Day 3 of adulthood, as reproduction declines. This suggests that the additive insult may arise from an age-related process. In patients with Down syndrome who carry an extra copy of *APP*, *APOE4* appears to hasten the onset of AD and accelerate the progression of neurodegeneration ([@bib48]; [@bib26]).

The synergy we observed for enhanced neurodegeneration by combining *APOE4* with *APP* did not extend to an APP-related gene in *C. elegans* called [*apl-1*](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486). In fact, we found a modest protective effect of overexpressing an extra copy of [*apl-1*](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486). [APL-1](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486) is highly homologous to the intracellular portion of APP ([Figure 2A](#fig2){ref-type="fig"}), but not the extracellular or Aβ portions of APP ([@bib14]). Because several clinical trials targeting Aβ have failed to ameliorate cognitive decline, further studies may shift to the role of the APP intracellular domain (AICD). The AICD has been implicated in enhancing AD through its roles in transcriptional activation, pro-apoptotic functions, cytoskeletal modifications, calcium homeostasis modulation, and tau phosphorylation ([@bib45]; [@bib8]; [@bib20]). In our model, a single extra copy of [APL-1](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486) appears mildly protective, but multicopy overexpression of [*apl-1*](https://identifiers.org/bioentitylink/WB:WBGene00000149?doi=10.1534/g3.120.401486) has shown defects in movement, brood size, development, chemotaxis, and learning paradigms ([@bib28]; [@bib16]). This suggests expression level may also play a role in disease progression. Future studies will need to determine whether neuroprotection against APOE4 stems from the homologous intracellular side and/or other pathways while paying careful attention to expression levels.

In humans, neurodegeneration occurs more extensively in certain regions of the brain, such as the hippocampus and entorhinal cortex ([@bib50]). This aspect is one of the more curious observations in AD patients because APP and APOE4 are both expressed throughout the brain ([@bib31]). Our results show that numerous VA and VB cholinergic neurons did not degenerate despite the pan-neuronal expression of *APP* and *APOE4* transgenes and their proximity to the vulnerable VC and HSN neurons. The restricted pattern of *APOE4*-dependent degeneration in worm suggests that there may be cellular and/or molecular characteristics that confer resistance (*e.g.*, VA and VB) or vulnerability (HSNs) to *APOE4*.

Although APOE4 is expressed in both the liver and the nervous system in human ([@bib27]; [@bib39]; [@bib41]), it is unclear whether hepatic, neuronal, or both types of APOE4 contribute to neurodegeneration. We were interested in exploring whether *APOE4*-induced degeneration is tissue-specific in worm. Recent studies have demonstrated clear examples of cell non-autonomous signaling between neuronal and non-neuronal tissue in *C. elegans* ([@bib55]; [@bib53]; [@bib42]). For instance, unfolded protein responses, which may underlie neurodegeneration, are interdependently co-activated between the nervous systems and the intestine ([@bib55]; [@bib53]). Additionally, when under stress worm neurons jettison particles extracellularly to become absorbed by coelomocytes ([@bib42]). Taken together, these studies suggest that *APOE4* could very well influence neurodegeneration when expressed outside of the neurons. However, after probing expression in both intestine and coelmocytes, our results indicate that *APOE4* mainly induces degeneration when expressed in the nervous system of *C. elegans*. These results are consistent with other work showing the sufficiency of neuronal *APOE4* expression in causing exacerbated cellular or behavioral deficits. For example, in mice neuronal *APP* can cause degeneration and memory deficits when co-expressed with *APOE4* ([@bib5]; [@bib25]).

To begin to understand the basis for neurodegeneration in our model, we asked whether degeneration of HSN neurons required apoptosis. [CED-3](https://identifiers.org/bioentitylink/WB:WBGene00000417?doi=10.1534/g3.120.401486) is the primary executioner caspase that initiates the cascade of apoptosis ([@bib63]). When a [*ced-3*](https://identifiers.org/bioentitylink/WB:WBGene00000417?doi=10.1534/g3.120.401486) null mutation was crossed into the APOE4+APP strain, we saw no reduction of the bag-of-worms phenotype or HSN neurodegeneration. This indicates that apoptosis is likely not involved in *APOE4*-dependent degeneration in *C. elegans*. Other *C. elegans* neurodegenerative models similarly show that [*ced-3*](https://identifiers.org/bioentitylink/WB:WBGene00000417?doi=10.1534/g3.120.401486) and other broad apoptotic mechanisms do not play a role in models of degeneration (*e.g.*, [@bib38]). Necrosis has been previously observed in models of neurodegeneration caused by a number of insults including hyperactive ion channels, increased intracellular Ca^2+^, and protein aggregate-induced stress ([@bib46]). Genetic and pharmacological manipulation of necrosis pathways have been previously described in worm, and the drug thapsigargin, a modulator of cytosolic Ca^2+^, has been shown to moderately repress neurodegeneration in worms expressing APOE4 and Aβ ([@bib7]; [@bib24]). We plan to use these and other methods to elucidate the mechanism of neurodegeneration in our APOE4 model in *C. elegans*. Our model is well-positioned to be used to explore how patterned neurodegeneration may arise in AD and other neurodegenerative diseases.

Supplemental material available at figshare: <https://doi.org/10.25387/g3.12493769>.
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